Only nine weeks after US approval, Trikafta, which in theory can treat 90% of all patients with cystic fibrosis, is already Vertex's top-selling medicine.
Analysts have been stunned by the launch of Vertex Pharmaceuticals Inc.'s Trikafta, with the first triple combination therapy for cystic fibrosis recording a whopping $420m in revenues iust nine weeks since US approval.
Wall Street had been estimating sales in the region of $30m-$70m for Trikafta (elexacaftor/ivacaftor/tezacaftor) which was approved by the US Food and Drug Administration on October 21 after a review lasting just three months
Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.
In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.
The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.
